Sign In
Buy PRNB
$100.05
+0 (+0%)
At Close: May 27, 2022
SHAREHOLDER ALERT: WeissLaw LLP Investigates Principia Biopharma Inc.
11:46pm, Monday, 17'th Aug 2020
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Principia Biopharma Inc. ("PRNB" or the "Company") (NASDAQ: PRNB) in connecti
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Principia Biopharma Inc. (Nasdaq - PRNB)
10:53pm, Monday, 17'th Aug 2020
BALA CYNWYD, PA / ACCESSWIRE / August 17, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Principia Biopharma Inc.
New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Principia Biopharma Inc. ("Principia
STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Principia Biopharma Inc. - PRNB
09:56pm, Monday, 17'th Aug 2020
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Principia Biopharm
Sanofi Acquiring Principia Biopharma for $3.7 Billion
08:57pm, Monday, 17'th Aug 2020
Sanofi (NASDAQ: SNY) announced a fresh acquisition on Monday morning. The sprawling pharmaceutical company said it has agreed to purchase biotech Principia Biopharma (NASDAQ: PRNB) for $100 per share
Sanofi Surprised No One With Its $3.7 Billion Deal for Principia. Its Stock Is Rising Anyway.
06:16pm, Monday, 17'th Aug 2020
The French pharmaceutical giant is digging into the cash it amassed earlier this year with the sale of its $11.7 billion stake in Regeneron.
New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Principia Biopharma Inc.
PRINCIPIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRNB and Encourages Investors to Contact the Firm
05:35pm, Monday, 17'th Aug 2020
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Principia Biopharma Inc. (NASDAQ: PRNB) breached their
PRINCIPIA BIOPHARMA INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
04:02pm, Monday, 17'th Aug 2020
WILMINGTON, Del., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Principia Biopharma Inc. (“Principia”) (NASDAQ GS: PRNB) regarding possible breaches o
Sanofi Stock Is Rising Following a $3.7 Billion Deal for a U.S. Biotech Firm
02:26pm, Monday, 17'th Aug 2020
The French pharmaceutical giant is digging into the cash it amassed earlier this year with the sale of its $11.7 billion stake in Regeneron.
NEW YORK, NY / ACCESSWIRE / August 17, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Principia Biopharma Inc.
Sanofi to Buy Immunology Firm Principia Biopharma for $3.7B
12:55pm, Monday, 17'th Aug 2020
Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?
12:37pm, Monday, 17'th Aug 2020
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc. ("Principia " or the "Company") (NASDAQ: PRNB) breached their f
Sanofi looks to accelerate MS treatment with $3.68 billion acquisition of Principia Biopharma
11:13am, Monday, 17'th Aug 2020
Sanofi Chief Executive Paul Hudson strikes his second biotech deal since taking over at the French drugmaker last year.
Oita Chuo Pacific Management Comments on Sanofi as They Agree to Acquire U.S. Biotech Firm Principia Biopharma
11:02am, Monday, 17'th Aug 2020
TOKYO--(BUSINESS WIRE)--Financial executives at Oita Chuo Pacific Management have commented on Sanofi agreeing to acquire U.S. Principia Biopharma for $3.4 billion.
